Go online to PeerView.com/VVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The targeted therapy landscape for non–small cell lung cancer (NSCLC) has evolved considerably in recent years, with far-reaching implications for oncologists, patholo
Publish Date: Jan 15, 2021
There are currently no snippets from Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guida.
Snippets are an easy way to highlight your favorite soundbite from any piece of
audio and share with friends, or make a trailer for PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
There are currently no playlists containing this audio.
Add this audio track to one of your playlists
Go online to PeerView.com/VVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The targeted therapy landscape for non–small cell lung cancer (NSCLC) has evolved considerably in recent years, with far-reaching implications for oncologists, pathologists, and other members of the broader lung cancer care team, as well as for patients. This educational activity provides a comprehensive overview of the importance of performing genomic profiling to determine the optimal treatment approach for patients with molecularly altered NSCLC. In addition, essential practical guidance is shared to help match targeted therapies to each patient’s genomic alteration for improved outcomes. Experts discuss the advances, new evidence, and best practices related to molecular testing and targeted treatment of NSCLC. Guidance for applying the emerging science to patient care decisions in everyday practice are also shared, along with recommendations and resources for patient education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of various molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the various approved and investigational targeted therapies for NSCLC in different patient populations (eg, those targeting EGFR, ALK, BRAF, NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others), Integrate best practices related to molecular testing through the continuum of advanced NSCLC, and interpretation of results to guide treatment selection, Educate patients with NSCLC and their caregivers about molecular testing and targeted therapy options to help them become well-informed participants in their care, Implement evidence-based, individualized, precision treatment plans for management of molecularly altered NSCLC based on results of molecular testing, specific patient needs and preferences, and other key factors.